| Literature DB >> 25438734 |
Suqin Guo1, Shriji Patel2, Ben Baumrind2, Keegan Johnson2, Daniel Levinsohn2, Edward Marcus2, Brad Tannen2, Monique Roy2, Neelakshi Bhagat2, Marco Zarbin2.
Abstract
Pseudophakic cystoid macular edema (PCME) is a common complication following cataract surgery. Acute PCME may resolve spontaneously, but some patients will develop chronic macular edema that affects vision and is difficult to treat. This disease was described more than 50 years ago, and there are multiple options for clinical management. We discuss mechanisms, clinical efficacy, and adverse effects of these treatment modalities. Topical non-steroidal anti-inflammatory agents and corticosteroids are widely used and, when combined, may have a synergistic effect. Intravitreal corticosteroids and anti-vascular endothelial growth factor (anti-VEGF) agents have shown promise when topical medications either fail or have had limited effects. Randomized clinical studies evaluating anti-VEGF agents are needed to fully evaluate benefits and risks. When PCME is either refractory to medical therapy or is associated with significant vitreous involvement, pars plana vitrectomy has been shown to improve outcomes, though it is associated with additional risks.Entities:
Keywords: anti-vascular endothelial growth factor; corticosteroids; non-steroidal anti-inflammatory agents; pars plana vitrectomy; pseudophakic cystoid macular edema
Mesh:
Substances:
Year: 2014 PMID: 25438734 DOI: 10.1016/j.survophthal.2014.08.005
Source DB: PubMed Journal: Surv Ophthalmol ISSN: 0039-6257 Impact factor: 6.048